{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:19:04Z","timestamp":1783185544076,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"publisher","award":["Z2025063"],"award-info":[{"award-number":["Z2025063"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118976","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:11:13Z","timestamp":1779376273000},"page":"118976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of a selective and effective CRBN-recruiting ATR degrader with strong antitumor activity"],"prefix":"10.1016","volume":"315","author":[{"given":"Lei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118976_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2021.01.041","article-title":"Functional interrogation of DNA damage response variants with base editing screens","volume":"184","author":"Cuella-Mattin","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118976_bib2","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1038\/s41467-019-13018-3","article-title":"Inhibition of DNA damage response at telomeres improves the detrimental phenotypes of hutchinson\u2013gilford progeria syndrome","volume":"10","author":"Aguado","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118976_bib3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ijc.32200","article-title":"Targeting the TLK1\/NEK1 DDR axis with thioridazine suppresses outgrowth of androgen independent prostate tumors","volume":"145","author":"Singh","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118976_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118976_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine and cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118976_bib6","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy","volume":"210","author":"Goreki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118976_bib7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118976_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118976_bib9","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-human study of the ataxia telangiectasia and Rad3-Related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118976_bib10","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the potent and selective ATR inhibitor camonsertib (RP-3500)","volume":"67","author":"B","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118976_bib11","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118976_bib12","article-title":"Discovery of selective and potent ATR degrader for exploration its kinase\u2010independent functions in acute myeloid leukemia cells","volume":"63","author":"Wang","year":"2024","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.118976_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118976_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"Crews. PROteolysis TArgeting fhimeras (protacs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2026.118976_bib15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Dhanusha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118976_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acs.biochem.9b00848","article-title":"PROTACs as potential therapeutic agents for cancer drug resistance","volume":"59","author":"Y Sun","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.118976_bib17","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/molecules28114521","article-title":"Design, synthesis, and biological evaluation of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase for the efficient treatment of cancer","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118976_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116159","article-title":"Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","volume":"267","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118976_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2026.118976_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300482","article-title":"A modular chemistry platform for the development of a cereblon E3 ligase-based partial PROTAC library","volume":"24","author":"Almod\u00f3var-Rivera","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.118976_bib21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/v11100938","article-title":"High fidelity deep sequencing reveals no effect of ATM, ATR, and DNA-PK cellular DNA damage response pathways on adenovirus mutation rate","volume":"11","author":"Risso-Ballester","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.118976_bib22","article-title":"Unveiling new Triazoloquinoxaline-based PROTACs designed for the selective degradation of the ncBAF chromatin remodeling subunit BRD9","volume":"8","author":"Pierri","year":"2025","journal-title":"Chemistry."},{"key":"10.1016\/j.ejmech.2026.118976_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ejmech.2026.118976_bib24","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1038\/s41467-020-18580-9","article-title":"ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration","volume":"11","author":"Kidiyoor","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118976_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.05.046","article-title":"ATR mediates a checkpoint at the nuclear envelope in response to mechanical stress","volume":"158","author":"Kumar","year":"2014","journal-title":"Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:13:23Z","timestamp":1783185203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"alternative-id":["S0223523426004216"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118976","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a selective and effective CRBN-recruiting ATR degrader with strong antitumor activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118976"}}